

Swedencare AB (publ) sets the additional purchase price for the acquisition of Animal Pharmaceuticals at the maximum amount of approximately 87 million SEK (10MUSD)

Swedencare has in accordance with the agreement regarding the acquisition of the operations of Animal Pharmaceuticals, which was announced on September 24th 2020, paid an additional purchase price of approximately 87 million SEK.

The additional purchase consideration is based on the established EBITDA result of 2.7MUSD during the period July 2019 - June 2020 in the acquired business. The total purchase price for the business amounted to approximately 218 million SEK. The additional purchase price is financed partly from own funds and through a bank loan of 65 million SEK.

For more information, please contact:

Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se

FNCA is the Certified Adviser of the Company
Phone: +46 (0) 8 528 00 399
Email: info@fnca.se

Please visit the Company homepage www.swedencare.se

About Swedencare

Swedencare develop, produce, market, and sell premium products on the global and fast-growing market within animal healthcare for cats, dogs and horses. The product groups ProDen PlaqueOff®, Stratford and NutriScience are represented on approximately fifty markets in all parts of the world through ten subsidiaries in the Nordics, United States, France, Spain, Greece, Great Britain and Ireland and with an external distribution network. Swedencare's sales have increased significantly over the last few years with strong margins and results. The board of directors and the management have a wide and extensive experience of international marketing and sales.

Press Release
17 November 2020 17:00:00 CET



Attachments

Swedencare AB (publ) sets the additional purchase price for the acquisition of Animal Pharmaceuticals at the maximum amount of approximately 87 million SEK (10MUSD)